Optimized chemical proteomics assay for kinase inhibitor profiling.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Proteome Research

• Publication date

  2015-02-20

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/pr5012608PMID 25660469
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global discovery of protein kinases and other nucleotide-binding proteins by mass spectrometry.

  2016cited by this paper
• Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy

  2014cited by this paper
• Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ *

  2014cited by this paper
• A new chemical probe for quantitative proteomic profiling of fibroblast growth factor receptor and its inhibitors.

  2014cited by this paper
• A Targeted Quantitative Proteomics Strategy for Global Kinome Profiling of Cancer Cells and Tissues*

  2014cited by this paper
• New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics.

  2014cited by this paper
• Mass-spectrometry-based draft of the human proteome

  2014cited by this paper
• Phenotypic screening in cancer drug discovery — past, present and future

  2014cited by this paper
• Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling.

  2013cited by this paper
• DMSO enhances electrospray response, boosting sensitivity of proteomic experiments

  2013cited by this paper
• Global proteome analysis of the NCI-60 cell line panel.

  2013cited by this paper
• Phenotypic screens as a renewed approach for drug discovery.

  2013cited by this paper
• Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity.

  2013cited by this paper
• A public-private partnership to unlock the untargeted kinome.

  2013cited by this paper
• Activity‐based kinase profiling of approved tyrosine kinase inhibitors

  2013cited by this paper
• Target identification for small bioactive molecules: finding the needle in the haystack.

  2013cited by this paper
• Characterization of a chemical affinity probe targeting Akt kinases.

  2013cited by this paper
• A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

  2013cited by this paper
• Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.

  2012cited by this paper
• Mass spectrometry-based proteomics in preclinical drug discovery.

  2012cited by this paper
• Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL.

  2012cited by this paper
• Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present

  2012cited by this paper
• Kinase inhibitor profiling using chemoproteomics.

  2012cited by this paper
• Predicting new indications for approved drugs using a proteochemometric method.

  2012cited by this paper
• Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen.

  2012cited by this paper
• PRKX, TTBK2 and RSK4 expression causes sunitinib resistance in kidney carcinoma‐ and melanoma‐cell lines

  2012cited by this paper
• Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.

  2012cited by this paper
• PRKX critically regulates endothelial cell proliferation, migration, and vascular-like structure formation.

  2011cited by this paper
• Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

  2011cited by this paper
• Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

  2011cited by this paper
• Comprehensive analysis of kinase inhibitor selectivity

  2011cited by this paper
• Chapter 1:The Kinome and its Impact on Medicinal Chemistry

  2011cited by this paper
• In situ kinase profiling reveals functionally relevant properties of native kinases.

  2011cited by this paper
• Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.

  2010cited by this paper
• Toward a unified approach to dose–response modeling in ecotoxicology

  2010cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

  2010cited by this paper
• Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo

  2010cited by this paper
• A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells

  2010cited by this paper
• Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.

  2010cited by this paper
• Selectively nonselective kinase inhibition: striking the right balance.

  2010cited by this paper
• Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis

  2010cited by this paper
• Identifying the proteins to which small-molecule probes and drugs bind in cells

  2009cited by this paper
• Large-scale Proteomics Analysis of the Human Kinome

  2009cited by this paper
• Proteomics strategy for quantitative protein interaction profiling in cell extracts

  2009cited by this paper
• Accurate and sensitive peptide identification with Mascot Percolator.

  2009cited by this paper
• Target profiling of small molecules by chemical proteomics.

  2009cited by this paper
• MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification

  2008cited by this paper
• A quantitative analysis of kinase inhibitor selectivity

  2008cited by this paper
• Target deconvolution strategies in drug discovery

  2007cited by this paper
• Patterns of somatic mutation in human cancer genomes

  2007cited by this paper
• Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

  2007cited by this paper
• Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

  2007cited by this paper
• The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models

  2006cited by this paper
• The Structure of Dimeric ROCK I Reveals the Mechanism for Ligand Selectivity*

  2006cited by this paper
• Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin.

  2005cited by this paper
• Inhibition of Rho Kinase (ROCK) Leads to Increased Cerebral Blood Flow and Stroke Protection

  2005cited by this paper
• A small molecule–kinase interaction map for clinical kinase inhibitors

  2005cited by this paper
• Drug repositioning: identifying and developing new uses for existing drugs

  2004cited by this paper
• In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

  2003cited by this paper
• The Protein Kinase Complement of the Human Genome

  2002cited by this paper
• Protein kinases — the major drug targets of the twenty-first century?

  2002cited by this paper
• Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities.

  2002cited by this paper
• Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage.

  2001cited by this paper
• Frequent Co‐Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines.

  1999cited by this paper
• Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension

  1997cited by this paper
• Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial.

  1992cited by this paper

• Data-Independent Acquisition Enhancement of a Competitive Activity-Based Protein Profiling Platform for Kinase Inhibitor Screening.

  2026cites this paper
• Automated High-Throughput Affinity Capture-Mass Spectrometry Platform with Data-Independent Acquisition.

  2025cites this paper
• The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity Against Plasmodium falciparum via Dual Inhibition of PfArk1 and Hemozoin Formation

  2025cites this paper
• Site-Specific Competitive Kinase Inhibitor Target Profiling Using Phosphonate Affinity Tags

  2025cites this paper
• Workflow for E3 Ligase Ligand Validation for PROTAC Development

  2025cites this paper
• Targeting Aurora Kinases as Essential Cell‐Cycle Regulators to Deliver Multi‐Stage Antimalarials Against Plasmodium Falciparum

  2025cites this paper
• A Probe-Based Target Engagement Assay for Kinases in Live Cells

  2025cites this paper
• Insights of affinity-based probes for target identification in drug discovery.

  2025cites this paper
• Global Protein-Ligand Binding Affinity Profiling via Photocatalytic Labeling

  2025cites this paper
• Targeting Aurora kinases as essential cell cycle regulators to deliver multi-stage antimalarials against Plasmodium falciparum

  2025cites this paper
• DDB1 engagement defines the selectivity of S656 analogs for cyclin K degradation over CDK inhibition

  2025cites this paper
• diaPASEF-Powered Chemoproteomics Enables Deep Kinome Interaction Profiling.

  2025cites this paper
• Quantitative proteomic mass spectrometry of protein kinases to determine dynamic heterogeneity of the human kinome

  2024cites this paper
• CellEKT: A Robust Chemical Proteomics Workflow to Profile Cellular Target Engagement of Kinase Inhibitors

  2024cites this paper
• Inhibiting Hippo pathway kinases releases WWC1 to promote AMPAR-dependent synaptic plasticity and long-term memory in mice

  2024cites this paper
• diaPASEF-Powered Chemoproteomics Enables Deep Kinome Interaction Profiling

  2024cites this paper
• Analytical Methods for Protein Kinase and Inhibitor Screening including Kinetic Evaluation

  2024cites this paper
• Streamlined analysis of drug targets by proteome integral solubility alteration indicates organ-specific engagement

  2024cites this paper
• A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction

  2024cites this paper
• Insights into the structural and functional activities of forgotten Kinases: PCTAIREs CDKs

  2024cites this paper
• Genomic Discovery and Structure–Activity Exploration of a Novel Family of Enzyme-Activated Covalent Cyclin-Dependent Kinase Inhibitors

  2024cites this paper
• Optimization of the Lead Compound NVP-BHG712 as Colorectal Cancer Inhibitor.

  2023cites this paper
• Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized Hit.

  2023cites this paper
• Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice

  2023cites this paper
• Differential Chemoproteomics Reveals MARK2/3 as Cell Migration‐Relevant Targets of the ALK Inhibitor Brigatinib

  2023cites this paper
• Chemoproteomic target deconvolution reveals Histone Deacetylases as targets of (R)-lipoic acid

  2023cites this paper
• Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted Treatment

  2023cites this paper
• High-Throughput Screening and Proteomic Characterization of Compounds Targeting Myeloid-Derived Suppressor Cells

  2023cites this paper
• Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2.

  2023cites this paper
• Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors

  2023cites this paper
• Merits of Diazirine Photo-Immobilization for Target Profiling of Natural Products and Cofactors

  2022cites this paper
• Illuminating kinase inhibitors biology by cell signaling profiling

  2022cites this paper
• Tackling polypharmacology of kinase inhibitors by transcription factor activity profiling.

  2022cites this paper
• The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy.

  2022cites this paper
• Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target

  2022cites this paper
• The emerging role of mass spectrometry-based proteomics in drug discovery

  2022cites this paper
• A recent update on small‐molecule kinase inhibitors for targeted cancer therapy and their therapeutic insights from mass spectrometry‐based proteomic analysis

  2022cites this paper
• Chemoproteomic profiling to identify activity changes and functional inhibitors of DNA-binding proteins.

  2022cites this paper
• Development of hetero-triaryls as a new chemotype for subtype-selective and potent Sirt5 inhibition.

  2022cites this paper
• Kinase inhibitor pulldown assay (KiP) for clinical proteomics

  2022cites this paper
• An overview of kinase downregulators and recent advances in discovery approaches

  2021cites this paper
• Mechanistic Insights into a CDK9 Inhibitor Via Orthogonal Proteomics Methods.

  2021cites this paper
• Proteomics‐based interrogation of the kinome and its implications for precision oncology

  2021cites this paper
• Chemical Phosphoproteomics Sheds New Light on the Targets and Modes of Action of AKT Inhibitors.

  2021cites this paper
• Missing Value Imputation using XGboost for Label-Free Mass Spectrometry-Based Proteomics Data

  2021cites this paper
• LanCLs add glutathione to dehydroamino acids generated at phosphorylated sites in the proteome.

  2021cites this paper
• Exploring the stability of inhibitor binding to SIK2 using molecular dynamics simulation and binding free energy calculation.

  2021cites this paper
• Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer.

  2021cites this paper
• The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors.

  2021cites this paper
• Mechanistic and Structural Features of PROTAC Ternary Complexes.

  2021cites this paper
• Selectivity aspects of activity-based (chemical) probes.

  2021cites this paper
• Recent Trends in rationally designed molecules as kinase inhibitors.

  2021cites this paper
• A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.

  2020cites this paper
• Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and Testing

  2020cites this paper
• A mass spectrometry-based proteome map of drug action in lung cancer cell lines

  2020cites this paper
• Functional characterization of a PROTAC directed against BRAF mutant V600E

  2020cites this paper
• PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase

  2020cites this paper
• Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib

  2020influential citation
• Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

  2020cites this paper
• Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens

  2020influential citation
• Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity.

  2019cites this paper
• Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.

  2019cites this paper
• Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms

  2019cites this paper
• Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells

  2019cites this paper
• Target engagement approaches for pharmacological evaluation in animal models.

  2019cites this paper
• Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.

  2019cites this paper
• Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.

  2019cites this paper
• Kinobeads: A Chemical Proteomic Approach for Kinase Inhibitor Selectivity Profiling and Target Discovery

  2019cites this paper
• Profiling the phosphotyrosine interactome of receptor tyrosine kinases by affinity enrichment-mass spectrometry

  2019cites this paper
• A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers

  2019cites this paper
• Chemoproteomic Selectivity Profiling of PIKK and PI3K Kinase Inhibitors.

  2019cites this paper
• Advances in kinome research of parasitic worms - implications for fundamental research and applied biotechnological outcomes.

  2018cites this paper
• NVP‐BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family

  2018cites this paper
• Chemoproteomic characterization of covalent target engagement in cells

  2018cites this paper
• Selective inhibition reveals cyclin-dependent kinase 2 as another kinase that phosphorylates the androgen receptor at serine 81.

  2018cites this paper
• The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells

  2018cites this paper
• Kinome chemoproteomics characterization of pyrrolo[3,4-c]pyrazoles as potent and selective inhibitors of glycogen synthase kinase 3.

  2018cites this paper
• Multi-Omics Profiling Establishes the Polypharmacology of FDA Approved CSK4/6 Inhibitors and Its Impact on Drug Response

  2018cites this paper
• New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome.

  2018cites this paper
• Kinase inhibitors: the road ahead

  2018cites this paper
• Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells*

  2018cites this paper
• How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?

  2018cites this paper
• Screening Strategies and Methods for Better Off-Target Liability Prediction and Identification of Small-Molecule Pharmaceuticals

  2018cites this paper
• Quantification and discovery of sequence determinants of protein‐per‐mRNA amount in 29 human tissues

  2018cites this paper
• Proteomic tools to study drug function

  2018cites this paper
• New opportunities for kinase drug repurposing and target discovery

  2018cites this paper
• Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis

  2018cites this paper
• Comprehensive characterization of the human proteome by multi-omic analyses

  2018cites this paper
• Chapter Ten - Chemical Biology in Drug Discovery

  2017cites this paper
• Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement

  2017cites this paper
• Approaches to identify kinase dependencies in cancer signalling networks

  2017cites this paper
• The target landscape of clinical kinase drugs

  2017influential citation
• Measuring Kinase Activity—A Global Challenge

  2017cites this paper
• Kinobead and Single-Shot LC-MS Profiling Identifies Selective PKD Inhibitors.

  2017cites this paper
• Advances in the development of human protein microarrays

  2017cites this paper
• Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis.

  2017cites this paper
• Chemoproteomics‐Aided Medicinal Chemistry for the Discovery of EPHA2 Inhibitors

  2017cites this paper
• Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer

  2017cites this paper
• Paradigm of Biased PAR1 (Protease-Activated Receptor-1) Activation and Inhibition in Endothelial Cells Dissected by Phosphoproteomics

  2017cites this paper
• Pharmacoproteomic characterisation of human colon and rectal cancer

  2017influential citation